Transcriptional profiling of Hutchinson-Gilford Progeria patients identifies primary target pathways of progerin

Sandra Vidak1, Sohyoung Kim2, Tom Misteli1

  • 1Cell Biology of Genomes, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.

Insights

Hutchinson Gilford Progeria Syndrome (HGPS) involves a mutation in the LMNA gene, causing premature aging. Transcriptomic analysis reveals key cellular pathway misregulations in patients, identifying primary targets of the disease-causing progerin protein.

Area of Science:

  • Genetics
  • Molecular Biology
  • Cell Biology

Background:

  • Hutchinson Gilford Progeria Syndrome (HGPS) is a rare genetic disorder characterized by premature aging.
  • It stems from a mutation in the LMNA gene, producing a toxic protein called progerin.
  • Understanding HGPS mechanisms is crucial due to its rarity and variable patient progression.

Purpose of the Study:

  • To investigate the clinical relevance of cellular pathways implicated in HGPS.
  • To assess gene expression heterogeneity among HGPS patients.
  • To identify primary molecular targets affected by progerin.

Main Methods:

  • Transcriptomic analysis of a comprehensive cohort of HGPS patients.
  • Comparison of patient transcriptomes with an inducible HGPS cellular model.
  • Identification of differentially expressed genes and affected cellular pathways.

Main Results:

  • Misexpression of signaling pathways, Unfolded Protein Response (UPR), and mesodermal cell fate specification observed across HGPS patients.
  • Limited variability in gene expression among individual patients.
  • Identification of mTORC1, UPR, UV response, apoptosis, and TNFα signaling as primary targets of progerin.

Conclusions:

  • Transcriptomic analysis provides insights into HGPS pathophysiology.
  • Key cellular pathways are consistently dysregulated in HGPS patients.
  • Identified targets offer potential avenues for therapeutic intervention in HGPS.